Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Abstract: The present invention relates to a combination product comprising (i) nitazoxanide (NTZ) or an analogue thereof, and (ii) a PPAR agonist, for use in the treatment of an immune diseases or inflammation.
Abstract: The invention relates to a novel method for the diagnosis of non-alcoholic steatohepatitis (NASH), and for classifying a subject as a potential receiver of a treatment for NASH.
Type:
Grant
Filed:
March 30, 2017
Date of Patent:
October 1, 2024
Assignee:
GENFIT
Inventors:
Raphaël Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Abstract: The present invention relates to a compound selected from nitazoxanide, tizoxanide and tizoxanide glucuronide, for use in a method for the treatment of sepsis in a subject in need thereof.
Type:
Application
Filed:
May 10, 2022
Publication date:
July 18, 2024
Applicant:
GENFIT
Inventors:
Vanessa LEGRY, Rémy HANF, Simon DEBAECKER
Abstract: The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.
Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Abstract: The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other blood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200. It also relates to a kit for implementing the method of the invention, and the compounds for use in a method for the treatment of NASH, wherein the subject to be treated is identified, evaluated or classified according to the method of the invention.
Type:
Application
Filed:
June 24, 2022
Publication date:
December 29, 2022
Applicant:
Genfit
Inventors:
Raphaël Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
Abstract: The present invention relates to a novel non-invasive method for the diagnosis of a non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, and/or liver fibrosis.
Type:
Grant
Filed:
September 14, 2018
Date of Patent:
December 6, 2022
Assignee:
Genfit
Inventors:
Remy Hanf, Genevieve Cordonnier, John Brozek
Abstract: The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other blood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200. It also relates to a kit for implementing the method of the invention, and the compounds for use in a method for the treatment of NASH, wherein the subject to be treated is identified, evaluated or classified according to the method of the invention.
Type:
Grant
Filed:
September 14, 2016
Date of Patent:
June 28, 2022
Assignee:
Genfit
Inventors:
Raphaël Darteil, Geneviève Cordonnier, John Brozek, Emilie Praca, Fouad Ben Sudrik
Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.